Ruifu Chemical is the leading supplier of (2S)-1-(Chloroacetyl)-2-Pyrrolidinecarbonitrile (CAS: 207557-35-5) with high quality, intermediate of Vildagliptin (CAS: 274901-16-5) in the treatment of Type 2 Diabetes Mellitus (T2DM).
Ruifu Chemical has been supplying pharmaceutical intermediates and API (active pharmaceutical ingredient) more than 15 years, can provide worldwide delivery, competitive price, excellent service.
Purchase (2S)-1-(Chloroacetyl)-2-Pyrrolidinecarbonitrile, please contact us by e-mail: alvin@ruifuchem.com
| Chemical Name |
(2S)-1-(Chloroacetyl)-2-Pyrrolidinecarbonitrile |
| Synonyms |
(S)-1-(Chloroacetyl)-2-Pyrrolidinecarbonitrile; (S)-1-(2-Chloroacetyl) pyrrolidine-2-Carbonitrile; (2S)-N-Chloroacetyl-2-Cyanotetrahydropyrrole;(S)-2-Pyrrolidinecarboxamide; Vildagliptin Impurity J; Vildagliptin Intermediate C |
| CAS Number |
207557-35-5 |
| Stock Status |
In Stock, Production Scale Up to Tons |
| Molecular Formula |
C7H9ClN2O |
| Molecular Weight |
172.61 |
| Melting Point |
64.0-68.0℃ |
| Density |
1.27±0.10 g/cm3 |
| Storage Conditions |
Store Under Inert Gas (Nitrogen or Argon) at 2-8℃ |
| Sensitive |
Air Sensitive, Heat Sensitive |
| Shelf Life |
24 Months When Properly Stored |
| COA & MSDS |
Available |
| Origin of Product |
Shanghai, China |
| Product Categories |
Pharmaceutical Intermediates |
| Brand |
Ruifu Chemical |
| Item |
Specifications |
Results |
| Appearance |
Off-White to White Crystalline Powder (Visual) |
Off-White Crystalline Powder |
| Identification |
RT Conform to Standard (HPLC) |
Complies |
| Specific Rotation [α]D20 |
-1.505° ~ -1.550° (C: 1.00g/100mL; CHCl3) |
-1.523° |
| Melting Point |
64.0~68.0℃ |
64.5~66.0℃ |
| Loss on Drying |
≤0.50% |
0.22% |
| Residue on ignition |
≤0.20% |
0.04% |
| Max. Unknown Impurity |
≤0.50% (HPLC) |
Complies |
| Total Impurities |
≤1.00% (HPLC) |
Complies |
| Purity / Analysis Method |
≥99.0% (HPLC) |
99.6% |
| Test Standard |
Enterprise Standard |
Complies |
Package: Fluorinated bottle, aluminium foil bag, 25kg/cardboard drum, or according to customer's requirement.
Storage Condition: Keep the container tightly closed. Store in a cool, dry (2-8℃) and well-ventilated warehouse away from incompatible substances. Prevent direct sunshine; avoid fire and heat sources; avoid moisture.
Shipping: Deliver to worldwide by air, by sea, by FedEx / DHL Express. Provide fast and reliable delivery.
How to Purchase? Please contact Dr. Alvin Huang: sales@ruifuchem.com or alvin@ruifuchem.com
15 Years Experience? We have more than 15 years of experience in the manufacture and export of a wide range of high quality pharmaceutical intermediates or fine chemicals.
Main Markets? Sell to domestic market, North America, Europe, India, Korea, Japanese, Australia, etc.
Advantages? Superior quality, affordable price, professional services and technical support, fast delivery.
Quality Assurance? Strict quality control system. Professional equipment for analysis include NMR, LC-MS, GC, HPLC, ICP-MS, UV, IR, OR, K.F, ROI, LOD, MP, Clarity, Solubility, Microbial limit test, etc.
Samples? Most products provide free samples for quality evaluation, shipping cost should be paid by customers.
Factory Audit? Factory audit welcome. Please make an appointment in advance.
MOQ? No MOQ. Small order is acceptable.
Delivery Time? If within stock, three days delivery guaranteed.
Transportation? By Express (FedEx, DHL), by Air, by Sea.
Documents? After sales service: COA, MOA, ROS, MSDS, etc. can be provided.
Custom Synthesis? Can provide custom synthesis services to best fit your research needs.
Payment Terms? Proforma invoice will be sent first after confirmation of order, enclosed our bank information. Payment by T/T (Telex Transfer), PayPal, Western Union, etc.
(2S)-1-(Chloroacetyl)-2-Pyrrolidinecarbonitrile (CAS: 207557-35-5) is an intermediate typically in the synthesis of Vildagliptin (CAS: 274901-16-5), which was developed by Novartis Pharmaceutical Co., Ltd, is another oral administrated inhibitor of Dipeptidyl peptidase-IV after Sitagliptin. In 2008, it is approved for marketing in the European Union for the treatment of type 2 diabetes.